Status:
COMPLETED
Predictive Value of NT-proBNP on MACEs After Acute Coronary Syndrome
Lead Sponsor:
Haseki Training and Research Hospital
Conditions:
Acute Coronary Syndrome
ST-segment Elevation Myocardial Infarction (STEMI)
Eligibility:
All Genders
18+ years
Brief Summary
The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) as a cardiac biomarker in predicting short-term major adverse cardiovascular events (MACEs) in patients with Acute coronary syndrome (...
Detailed Description
In patients diagnosed with Acute coronary syndrome (ACS) based on anamnesis, clinical findings, electrocardiogram (ECG), and/or serum high-sensitivity cardiac troponin (hs-cTn) level in the emergency ...
Eligibility Criteria
Inclusion
- Adult patients (≥18 years old) who were admitted to the emergency department with Acute coronary syndrome and underwent percutaneous coronary intervention between September 2023 and February 2024.
Exclusion
- patients younger than 18 years
- patients had no vascular lesions detected on percutaneous coronary intervention,
- patients had infective or structural cardiac pathologies (myocarditis, pericarditis, hypertrophic or dilated cardiomyopathies)
- patients had chronic heart failure with LVEF \<40%, class 3 and 4 in the Killip classification
- patients had a diagnosis of malignancy, chronic renal failure, chronic liver failure, and a history of multiple trauma or surgery within the last month
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
241 Patients enrolled
Trial Details
Trial ID
NCT06569511
Start Date
September 1 2023
End Date
March 1 2024
Last Update
August 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haseki Training and Research Hospital
Istanbul, Fatih, Turkey (Türkiye), 34265